Opioid-Related Disorders Clinical Trial
— KIOS-IOfficial title:
Informational App Development for mHealth for Patient Self-Management of Opioid Use Disorder
Verified date | December 2023 |
Source | Biomedical Development Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will evaluate the feasibility of an app that provides drug information to people in recovery from opioid use disorder. This study is designed to test the prototype app, not to determine health outcomes. The study will confirm the design and operating specifications prior to being evaluated in a larger clinical trial.
Status | Active, not recruiting |
Enrollment | 25 |
Est. completion date | January 10, 2024 |
Est. primary completion date | January 10, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Male or female outpatients 18 years of age or older - Currently enrolled in an opioid treatment program and receiving medication assisted treatment for opioid use disorder - Currently stable in opioid use disorder outpatient treatment for 4 weeks or longer - Ability to access the app via smart phone, or tablet. Exclusion Criteria: - Unwilling or unable to comply with study requirements - Have a psychiatric or medical disorder interfering with ability to use the app - Incarcerated - Pregnant |
Country | Name | City | State |
---|---|---|---|
United States | UT Health San Antonio | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
Biomedical Development Corporation | National Institute on Drug Abuse (NIDA), The University of Texas Health Science Center at San Antonio |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Usability Score | The Systems Usability Scale-Modified is a non-health outcome, single-factor, 10-item self-report scale commonly used to evaluate participants' subjective experience using software. Systems Usability Scale yields a single number representing a composite measure of the overall usability of the system being studied. Systems Usability Scale scores have a range of 0 to 100, with higher scores representing a better outcome. Systems in early development may expect to have a rating of 30, while more mature systems should rate between 60 - 80. | The Systems Usability Scale will be administered at the end of one-week for participants enrolled in Step 1 of the study and at the end of four-weeks for participants enrolled in Step 2. | |
Secondary | User Satisfaction | A user satisfaction survey will be administered to evaluate the study participants' overall satisfaction with the app. This is a non-health outcome designed to better understand the user's perception of the app. The survey will consist of 20 statements that users will rate on a 1-7 Likert type scale (1=Disagree, 7= Agree). Satisfaction scores will be averaged and converted to percentages with higher percentages representing better user satisfaction with the app. | A user satisfaction survey will be administered at the end of one-week for participants enrolled in Step 1 of the study and at the end of four-weeks for participants enrolled in Step 2. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03950492 -
Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder
|
N/A | |
Completed |
NCT00000335 -
Activity Monitoring Assessment of Opiate Withdrawal - 4
|
Phase 2 | |
Active, not recruiting |
NCT03949764 -
The Kentucky Viral Hepatitis Treatment Study
|
Phase 4 | |
Enrolling by invitation |
NCT06084221 -
Fatal Overdose Review Teams - Research to Enhance Surveillance Systems
|
N/A | |
Completed |
NCT02978417 -
Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings
|
Phase 4 | |
Withdrawn |
NCT03137017 -
A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults
|
Phase 1 | |
Withdrawn |
NCT03137030 -
A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults
|
Phase 1 | |
Completed |
NCT02282306 -
Phone Interview to Prevent Recurring Opioid Overdoses
|
N/A | |
Completed |
NCT00710385 -
Abuse Liability of Suboxone Versus Subutex
|
Phase 3 | |
Completed |
NCT00142935 -
Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1
|
N/A | |
Completed |
NCT00218309 -
Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals
|
Phase 2 | |
Terminated |
NCT00000243 -
Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone
|
N/A | |
Completed |
NCT00067184 -
Fetal Neurobehavioral Development in Methadone Maintained Pregnancies
|
||
Completed |
NCT00000264 -
Subjective/Psychomotor/ Effects of Combined Alcohol & Nitrous Oxide - 16
|
N/A | |
Completed |
NCT00000257 -
Effects of Alcohol History on Effects of Nitrous Oxide - 9
|
N/A | |
Completed |
NCT00000306 -
Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3
|
Phase 2 | |
Completed |
NCT00000279 -
Novel Medications for Opiate Detoxification - 4
|
Phase 2 | |
Completed |
NCT00000249 -
Effects of Subanesthetic Concentrations of Nitrous Oxide - 1
|
Phase 2 | |
Recruiting |
NCT04933084 -
Pre-operative Education Modalities to Decrease Opioid Use
|
N/A | |
Recruiting |
NCT03610672 -
Mobile Intervention for Young Opioid Users
|
N/A |